Thermo Fisher Scientific, Inc.

The collaborative effort drives awareness about biomarker testing to the metastatic breast cancer community WASHINGTON, Oct. 30, 2024 /PRNewswire/ -- LUNGevity Foundation, a nationally recognized nonprofit dedicated to transforming how people are diagnosed and live with lung cancer through research, education, and support, is proud to announce a partnership with Living Beyond Breast Cancer (LBBC), a nationally recognized nonprofit dedicated to providing trusted information for people at every stage of their breast cancer journey, to spread awareness about biomarker testing for people diagnosed with metastatic breast cancer through the No One Missed: Breast Cancer campaign. The successful No One Missed: Lung Cancer campaign launched in 2021 and has reached millions of people with the importance of biomarker testing – specific drivers in a person's cancer that cause the cancer to grow and spread in different ways – at diagnosis and progression. With the support of campaign founding partner AstraZeneca and additional sponsors, the No One Missed: Breast Cancer campaign launched in June and is rapidly reaching a new audience. As with lung cancer, biomarker testing is a powerful tool that plays a critical role in understanding and guiding treatment decisions for those living with metastatic breast cancer (MBC). However, not all patients with MBC receive biomarker testing at the time of diagnosis and when there is cancer progression. There is no cure for MBC despite clinical advancements, with one-third of women diagnosed in the US living at least 5 years after diagnosis. However, knowing the presence of biomarkers can help those living with MBC and their healthcare teams make better treatment decisions. "As the understanding of metastatic breast cancer grows and more treatment options become available, biomarker testing has become a game changer to help patients and their doctors make more informed decisions," said Jean Sachs, MSS, MLSP, Chief Executive Officer, Living Beyond Breast Cancer. "For someone living with metastatic breast cancer, their cancer may evolve and their biomarkers may change. This signifies an important need for conversations between patients and healthcare teams about biomarker testing at diagnosis and every time a cancer progresses." "LUNGevity is proud to partner with Living Beyond Breast Cancer to expand the reach of the No One Missed campaign," said Andrea Ferris, president and CEO, LUNGevity Foundation. "We hope this resource will help improve patient and doctor conversations about biomarker testing." "In the US, 1 in 8 women will be diagnosed with breast cancer in their lifetime," said Mohit Manrao, Senior Vice President, US Oncology Business Unit, AstraZeneca. "We're proud to partner with organizations like LUNGevity Foundation and Living Beyond Breast Cancer to change these numbers and ensure patients have access to critical resources and information to better understand the unique qualities of their cancer, and ultimately ensure they receive the right treatment at the right time." About the No One Missed Campaign No One Missed is a community-led campaign driven by LUNGevity Foundation and supported by patient advocacy, pharmaceutical, and biotechnology organizations. The campaign's mission is to build public awareness of biomarker testing as a critical part of a cancer diagnosis and prognosis and empower patients to discuss biomarker testing with their healthcare team. No One Missed: Lung Cancer is supported by founding partner AstraZeneca, supporting member Daiichi-Sankyo, members Merck and Regeneron, and supporters Boehringer Ingelheim, Foundation Medicine, Genentech, Pfizer, Taiho Oncology, Takeda Oncology, and Thermo Fisher Scientific. Supporting partners include AONN, ALK Positive, AEACap, EGFR Resisters, Exon20Group, IASLC, KRAS Kickers, MET Crusaders, NTRKers, ONS, RETpositive, The ROS1ders, and US Oncology Research. No One Missed: Breast Cancer is supported by premier sponsor AstraZeneca; member sponsors Daiichi-Sankyo, Lilly, Merck, and Genentech; supporter sponsor Novartis; and friend sponsors Foundation Medicine and Relay Therapeutics. Additionally, No One Missed: Breast Cancer is supported by partners Breastcancer.org, Cancer Support Community, FORCE, Metastatic Breast Cancer Alliance, SHARE, Susan G. Komen, The Chrysalis Initiative, TOUCH: The Black Breast Cancer Alliance, and Young Survival Coalition. About Living Beyond Breast Cancer Living Beyond Breast Cancer is a national nonprofit organization that seeks to create a world that understands there is more than one way to have breast cancer. To fulfill its mission of providing trusted information and a community of support to those impacted by the disease, Living Beyond Breast Cancer offers in-person experiences and on-demand emotional, practical, and evidence-based content that is meaningful to those newly diagnosed, in-treatment, post-treatment and living with metastatic disease. Visit for more information. About LUNGevity Foundation LUNGevity, the nation's leading lung cancer organization, is transforming what it means to be diagnosed and live with lung cancer. LUNGevity seeks to make an immediate impact on quality of life and survivorship for everyone touched by the disease—while promoting health equity by addressing disparities throughout the care continuum. Through research, we use an innovative and holistic approach to finding lung cancer earlier when it is most treatable; advance research into new treatments so people may live longer and better; and ensure a diverse, vital pipeline of investigators for the future of the lung cancer field. Through advocacy, we foster groundbreaking collaborations to ensure all people have access to screening, biomarker testing, and treatment breakthroughs. Through community, we educate, support, and connect people affected by lung cancer so that they can get the best healthcare and live longer and better lives. Comprehensive resources include a medically vetted and patient-centric website, Patient Gateways for specific types of lung cancer, a toll-free HELPLine for personalized support, international survivor conferences, and tools to find a clinical trial. All these programs are designed to help us achieve our vision—a world where no one dies of lung cancer. LUNGevity Foundation is proud to be a four-star Charity Navigator organization. Please visit to learn more. SOURCE LUNGevity Foundation WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

NEW YORK, Oct. 23, 2024 /PRNewswire/ -- Report on how AI is driving market transformation - The Global Human Platelet Lysate Market size is estimated to grow by USD 0.011 million from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of 3.64% during the forecast period. Rising prevalence of chronic diseases is driving market growth, with a trend towards growing investments in stem cell research. However, stringent regulations and quality control requirements for human-derived products poses a challenge - Key market players include Amerigo Scientific, AventaCell BioMedical Corp. Ltd., BioLife Solutions Inc., Compass Biomedical Inc., Creative Biolabs, GeminiBio, Macopharma SA, Merck KGaA, Mill Creek Life Sciences Inc., MP Biomedicals Inc., PAN-Biotech GmbH, PL BioScience GmbH, Regenexx Des Moines, Sartorius AG, Sartorius CellGenix GmbH, Serana Europe GmbH, STEMCELL Technologies Inc., TCS Biosciences Ltd., TRINOVA BIOCHEM GmbH, and ZenBio Inc.. Continue Reading Technavio has announced its latest market research report titled Global human platelet lysate market 2024-2028 Key insights into market evolution with AI-powered analysis. Explore trends, segmentation, and growth drivers- View the snapshot of this report Market Driver The human platelet lysate market is experiencing significant growth due to increasing investments in stem cell research. Stem cells, with their potential to treat various diseases, necessitate high-quality cell culture supplements for growth and differentiation. Human platelet lysate, abundant in growth factors and cytokines, is a preferred choice in this field due to its compatibility with human cells and efficient cell proliferation properties. For instance, the California Institute for Regenerative Medicine (CIRM) recently approved an USD89 million investment for stem cell and gene therapy research, with nearly USD39 million allocated to four projects in CIRM's Clinical program. As stem cell and gene therapy advance, the demand for human platelet lysate will increase, driven by its crucial role in cell culture and regenerative medicine. Consequently, the global human platelet lysate market is expected to witness substantial growth during the forecast period, fueled by continued investments from governments, academic institutions, and biopharmaceutical companies in stem cell research. The Human Platelet Lysate market is experiencing significant growth due to increasing trends in personalized treatment solutions. This innovative biomedical product derived from human blood platelets is gaining popularity in various industries, including orthopedics and dermatology. Animal-derived supplements are being replaced with high-quality human platelet lysate for osteoarthritis treatment and cartilage regeneration. Key players in this market include cutting-edge innovators, providing active ingredients for therapeutic applications. Manufacturing obstacles and safety regulations are being addressed with efficient cell culture techniques and safety measures. Ethical considerations and contagious diseases are also prioritized, ensuring the highest standards. Applications extend to hair regrowth treatments in clinics and cytokines for neurodegenerative disorders like Parkinson's Disease and stem cell research. With a tailored strategy, regulatory landscape, and focus on safety and efficiency, the human platelet lysate market is poised for continued growth in the realm of regenerative medicine and tissue engineering. Request Sample of our comprehensive report now to stay ahead in the AI-driven market evolution! Market Challenges The human platelet lysate market faces substantial regulatory challenges, impacting product development and commercialization. Regulatory bodies like the FDA in the US and EMA in Europe impose rigorous requirements on human-derived product collection, processing, and testing to ensure safety and efficacy. These stringent regulations add to the cost and complexity of bringing products to market. Moreover, varying requirements in different countries can complicate global market entry. Companies must also maintain consistent product quality and adhere to safety protocols, such as those outlined in the ICH guidelines. Keeping up with evolving regulations and guidelines is essential. Overall, these regulatory hurdles pose a significant challenge to the growth of the global human platelet lysate market. The Human Platelet Lysate (HPL) market is witnessing significant growth due to its increasing applications in various clinical fields. One of the major challenges in this market is the shift towards Heparin-Free HPL, which is gaining popularity due to its compatibility with stem cell therapy and clinical trials. Heparin, a common anticoagulant used in traditional HPL, can negatively impact cell performance and reproducible results. Moreover, the market is witnessing an increasing focus on innovative treatments for chronic diseases such as cancer therapy and wound healing. Biotechnology companies are investing in the development of standardized, safe, and effective HPL for clinical applications. Pharmaceutical and healthcare facilities are exploring patent license agreements to manufacture and distribute HPL for various disease indications. Biogelx, a leading stem cell platform, is at the forefront of this trend, offering HPL for cell culture systems and tissue repair. HPL is rich in platelet-derived growth factors, which play a crucial role in cellular proliferation, angiogenesis, fibroblast proliferation, and extracellular matrix production. The market is also witnessing an increasing focus on the use of HPL in infectious diseases, drug discovery, and cell-based therapeutics. In conclusion, the Human Platelet Lysate market is a dynamic and growing industry, driven by the need for safe, effective, and reproducible results in various clinical applications, including stem cell therapy, clinical trials, chronic diseases, and tissue repair. Companies that can offer standardized and safe HPL are well-positioned to capitalize on this trend. Discover how AI is revolutionizing market trends- Get your access now! Segment Overview This human platelet lysate market report extensively covers market segmentation by Type 1.1 Heparin free human platelet lysate 1.2 Human platelet lysate with heparin Application 2.1 Research use 2.2 Clinical use Geography 3.1 North America 3.2 Europe 3.3 Asia 3.4 Rest of World (ROW) 1.1 Heparin free human platelet lysate- The Human Platelet Lysate market is experiencing significant growth due to its increasing usage in various research applications, particularly in biotechnology and pharmaceuticals. This market is driven by the rising demand for advanced diagnostic tools and therapeutic treatments. Key players in this market include Thermo Fisher Scientific, Sigma-Aldrich, and Gibco. These companies provide high-quality human platelet lysate products to meet the growing demand from researchers and healthcare professionals. Download a Sample of our comprehensive report today to discover how AI-driven innovations are reshaping competitive dynamics Research Analysis The Human Platelet Lysate (HPL) market is a significant segment of the biomedical industry, playing a crucial role in regenerative medicine, cell culture techniques, and therapeutic applications. HPL is derived from human platelets and contains various cytokines, growth factors, and other bioactive molecules that promote cellular proliferation, differentiation, and healing. HPL is used extensively in stem cell research, tissue engineering, and cell therapy for chronic diseases such as Parkinson's disease, neurodegenerative disorders, and injuries. Safety and efficiency are paramount in the production of HPL, with ethical considerations also being a significant factor. Fetal bovine serum (FBS) has traditionally been used as a supplement in cell culture, but HPL offers several advantages, including standardized, safe, and reproducible results. HPL is also heparin-free, making it an attractive alternative for pharmaceutical and healthcare facilities. The regulatory landscape for HPL is evolving, with clinical trials underway for various applications, including cancer therapy, wound healing, and infectious diseases. Innovative treatments using HPL are being explored in biotechnology, and the market is expected to grow significantly in the coming years due to its clinical applications in chronic diseases and therapeutic uses. Biogelx, for instance, is a leading provider of HPL for research and therapeutic applications, offering high-quality and consistent products for cell performance and differential potential. Market Research Overview The Human Platelet Lysate (HPL) market is a significant segment in the biomedical industry, playing a crucial role in regenerative medicine, cell culture techniques, and therapeutic applications. HPL is derived from platelets, which contain various bioactive compounds such as cytokines, platelet-derived growth factors, and other growth factors that promote cellular proliferation, angiogenesis, fibroblast proliferation, and extracellular matrix production. HPL is used in various clinical applications, including stem cell therapy for neurodegenerative disorders like Parkinson's disease, chronic diseases, and innovative treatments for infectious diseases. The regulatory landscape for HPL is stringent due to safety considerations, and manufacturers must adhere to ethical guidelines and quality standards. HPL is used in biotechnology and pharmaceutical industries for drug discovery and cell-based therapeutics, as well as in healthcare facilities for wound healing, cancer therapy, and tissue repair. The market for HPL is growing due to the increasing demand for high-quality solutions for personalized treatment and the development of heparin-free HPL and innovative cell culture systems. However, manufacturing obstacles and safety regulations pose challenges to the market's growth. Overall, the HPL market is a cutting-edge and active area of research, with potential applications in various industries and clinical indications. Table of Contents: 1 Executive Summary 2 Market Landscape 3 Market Sizing 4 Historic Market Size 5 Five Forces Analysis 6 Market Segmentation Type Heparin Free Human Platelet Lysate Human Platelet Lysate With Heparin Application Research Use Clinical Use Geography North America Europe Asia Rest Of World (ROW) 7 Customer Landscape 8 Geographic Landscape 9 Drivers, Challenges, and Trends 10 Company Landscape 11 Company Analysis 12 Appendix About Technavio Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios. Contacts Technavio Research Jesse Maida Media & Marketing Executive US: +1 844 364 1100 UK: +44 203 893 3200 Email: [email protected] Website: SOURCE Technavio WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Thermo Fisher told investors it is ready to shut the door on 2024, anticipating biotech funding to improve and lingering business insecurity caused by the Covid-19 pandemic to dissipate in 2025. “Confidence in biotech is improving and funding has been modestly improving as the year progresses,” CEO Marc Casper said during an earnings call Wednesday. Manufacturers have recently faced biopharma cost cuts, with companies shrinking their drug development pipelines, specifically Covid-19 companies that cut their production needs. But Thermo Fisher said this year will likely be the final year Covid-19 will impact the manufacturing business. The Inflation Reduction Act, the Biosecure Act and the Novo-Catalent deal have also caused biopharma clients to be cautious about what projects to move forward with. But Casper said Thermo Fisher is a “trusted partner” and “well positioned in the customer base” now that there’s more clarity on how these issues may play out. The renewed confidence in the manufacturing business has Thermo Fisher expecting improved sales as soon as the fourth quarter of this year, Casper said. William Blair analysts are also “optimistic” that funding is “accelerating.” While the manufacturer anticipates overall improvement, Casper said that the current market in China is “incredibly muted,” noting that “China has not progressed right in terms of economic activity.” Last week, Merck KGaA said its manufacturing business is also facing headwinds in China. In the third quarter, Thermo Fisher reported a “flat” revenue of $10.6 billion, compared with $10.57 billion in the same period last year, according to the company’s earnings report on Wednesday.